Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00350597 · ClinicalTrials.gov registry record · Phase 2
GM-CSF as Adjuvant Therapy of Melanoma
A Phase 2 study of Malignant Melanoma, sponsored by Northern California Melanoma Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00350597: Completed Phase 2 study of Malignant Melanoma, sponsored by Northern California Melanoma Center.
NCT00350597 is a Phase 2 study of Malignant Melanoma that has completed, run by Northern California Melanoma Center. The registered enrollment target is 50 participants, below the 181-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00350597, a Phase 2 study of Malignant Melanoma, has completed, sponsored by Northern California Melanoma Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a pilot study to describe the immunological responses and clinical outcome associated with administration of recombinant human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) as surgical adjuvant therapy in patients with malignant melanoma who are at high risk for recurrence (Stage II T4, III and IV).
Conditions Studied
Interventions
- DRUG Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
Study Locations (1)
California
- Northern California Melanoma Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2004-09 |
| Est. Completion | 2010-07 |
| Phase | Phase 2 |
What the finished NCT00350597 record still lists
NCT00350597 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 181-participant average among 28 other Malignant Melanoma trials with a reported enrollment target (72% lower).
The record links to 1 condition, with Malignant Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) is the first listed.
NCT00350597 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT00350597 about?
NCT00350597 is a clinical study titled "GM-CSF as Adjuvant Therapy of Melanoma". This is a pilot study to describe the immunological responses and clinical outcome associated with administration of recombinant human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) as surgical adjuvant therapy in patients with malignant melanoma who are at high risk for recurrence (Stage...
What is the current status of trial NCT00350597?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2004-09. Estimated completion is 2010-07.
What conditions does trial NCT00350597 study?
This clinical trial studies the following conditions: Malignant Melanoma.
What interventions are being tested in trial NCT00350597?
The interventions under investigation include: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) (DRUG).
Who is sponsoring clinical trial NCT00350597?
This trial is sponsored by Northern California Melanoma Center, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00350597 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00350597's enrollment target sits among peer trials
50 15th of 28 higher than 14 of 28 other Malignant Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study of V940 and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
RECRUITING · Phase 2
-
Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Combination Treatment With HF10 and Ipilimumab in Patients With Unresectable or Metastatic Melanoma
COMPLETED · Phase 2
-
Phase II Trial of Allovectin-7® for Metastatic Melanoma
COMPLETED · Phase 2
-
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
RECRUITING
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia